Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Paula Tagliani

Paula Tagliani

Institutions of which they are part

Predoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Paula Tagliani

Paula Tagliani

Paula Tagliani

Institutions of which they are part

Predoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Related news

Laboratori

Viva in Vitro and Vall d’Hebron will study biomarkers in multiple sclerosis

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Dr Mar Tintoré and Dr Álvaro Cobo Calvo

Ovarian reserve does not predict the course of multiple sclerosis

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

Els Drs. Montalban, Tintoré i Tur

Vall d’Hebron takes a further step towards individualized prediction of multiple sclerosis

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

See more

Related professionals

Carles Zafon Llopis

Carles Zafon Llopis

Main researcher
Diabetes and Metabolism
Read more
Pablo Castillo Sánchez

Pablo Castillo Sánchez

Research technician
Neurodegenerative Diseases
Read more
Amarilis Sofia Baekelandt

Amarilis Sofia Baekelandt

Research technician
Cardiovascular Diseases
Read more
Joaquim Vives Armengol

Joaquim Vives Armengol

Main researcher
Musculoskeletal Tissue Engineering
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.